RITA Medical to Present at the 2006 Robins Emerging Opportunities Investment Conference
15 5월 2006 - 8:30PM
PR Newswire (US)
FREMONT, Calif., May 15 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA), a publicly-traded medical device
company focused solely on cancer therapies, today announced that it
has been invited to present at the 2006 Robins Emerging
Opportunities Investment Conference, which will take place at the
University Club in New York City. The Company is scheduled to
discuss its business strategy and historical financial performance
on Wednesday, May 17, 2006 at 10:45 a.m. Eastern Time. Attendance
at the conference is by invitation only. RITA Medical will offer a
live audio webcast of its presentation which may be accessed at the
Company's website at http://www.ritamedical.com/. An archived
replay of the presentation will also be available approximately
three hours following the live presentation and will be available
at http://www.ritamedical.com/ for 90 days. About RITA Medical
Systems, Inc. RITA Medical Systems develops, manufactures and
markets innovative products for cancer patients including
radiofrequency ablation (RFA) systems and embolization products for
treating cancerous tumors as well as percutaneous vascular and
spinal access systems. The Company's oncology product lines include
implantable ports, some of which feature its proprietary Vortex(R)
technology; tunneled central venous catheters; and safety infusion
sets and peripherally inserted central catheters used primarily in
cancer treatment protocols. The radiofrequency product line also
includes the HABIB 4X resection device which coagulates a "surgical
resection plane" and is designed to facilitate a fast dissection in
order to minimize blood loss and blood transfusion during surgery.
The proprietary RITA RFA system uses radiofrequency energy to heat
tissue to a high enough temperature to ablate it or cause cell
death. In March 2000, RITA became the first RFA company to receive
specific FDA clearance for unresectable liver lesions in addition
to its previous general FDA clearance for the ablation of soft
tissue. In October 2002, RITA again became the first company to
receive specific FDA clearance, this time for the palliation of
pain associated with metastatic lesions involving bone. The Company
also distributes LC Bead embolic microspheres in the United States.
The LC Bead microspheres are injected into selected vessels to
block the blood flow feeding a tumor, causing it to shrink over
time, and are often used in combination with radiofrequency
ablation (RFA). The RITA Medical Systems website is at
http://www.ritamedical.com/. DATASOURCE: RITA Medical Systems, Inc.
CONTACT: investors, Doug Sherk or Jennifer Beugelmans,
+1-415-896-6820, or , or media, Steve DiMattia, +1-646-277-8706, or
, all of the EVC Group, for RITA Medical Systems, Inc.; or Joseph
DeVivo, President and CEO of RITA Medical Systems, Inc.,
+1-510-771-0400 Web site: http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Rita Medical (NASDAQ:RITA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Rita Medical Systems (나스닥)의 실시간 뉴스: 최근 기사 0
More Rita Medical Systems (MM) News Articles